The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.

A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who ...

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

From relentless claim denials and payer pressures to policy debates around prior authorization and the 340B program, this mid-year briefing unpacks the six essential stories every revenue cycle leader ...

Johnson & Johnson failed to convince a federal judge that the US government acted unlawfully when it rejected the company’s ...

Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...

The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the ...

A federal judge in D.C. recently ruled in favor of the U.S. Health Resources and Services Administration by finding that drug manufacturers must obtain pre-approval from HRSA before implementing ...

The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s law on 340B pricing for contract pharmacy ...